Bio-Rad Launches New Anti-tTG Assays for Celiac Disease

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of clinical diagnostics products and leader in autoimmune testing, announced today the launch of anti-tissue transglutaminase (tTG) assay IgA and IgG assays for celiac disease. The new assays are FDA-cleared, CE-marked and automation-ready.

The Bio-Rad anti-tTG assay is a solid phase enzyme immunoassay for the semi-quantitative and qualitative detection of antibodies against tissue transglutaminase (tTG) in human serum. Each assay contains 12 eight-well breakaway ELISA strips for economy of use, pre-diluted calibrators for flexible quantitative and qualitative calibration, color-coded reagents and reagent bottles for ease of use. Each assay is designed to be easily adaptable on an automation platform. The new assays share the common protocol with other Bio-Rad autoimmune EIA assays.

Celiac disease is one of the most common, lifelong disorders in the western countries. It is characterized by immune-mediated damage to the jejunal mucosa of the gastrointestinal tract that is triggered by gluten, a protein found in wheat, rye and barley. Due to its wide spectrum of clinical symptoms, celiac disease is often misdiagnosed or under-diagnosed.

Bio-Rad anti-tTG assays are new generation of anti-tTG kits with increased sensitivity and specificity for celiac disease diagnosis. More celiac patients will be identified when screening with the Bio-Rad tTG assays, giving clinical laboratories more confidence in their testing results and providing a better outcome for the patients.